Macrocyclic FXIa Inhibitors for Safer Anticoagulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulants for treating thromboembolic disorders, such as warfarin, have limitations including a narrow therapeutic index, slow onset of action, and require monitoring, highlighting the need for safe and efficacious oral anticoagulants that can effectively inhibit thrombin generation.
Innovation Solution
Development of novel macrocyclic compounds that selectively inhibit serine protease enzymes like factor XIa and plasma kallikrein, which are used in pharmaceutical compositions for the treatment and prophylaxis of thromboembolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If warfarin is used as an anticoagulant, then thrombin generation is inhibited, but the therapeutic index is narrow and monitoring is required
Solution Approach 1:
The patent develops novel macrocyclic compounds with modified chemical structures compared to warfarin, changing the pharmacological parameters to achieve broader therapeutic index and reduced monitoring requirements while maintaining anticoagulant efficacy through selective factor XIa inhibition
Solution Approach 2:
The patent extracts and targets the specific enzymatic step of factor XIa activation in the coagulation cascade, rather than inhibiting multiple coagulation factors simultaneously as warfarin does, thereby achieving more selective inhibition with improved safety profile and reduced monitoring needs
2Reliability
If warfarin is used as an anticoagulant, then thrombin generation is inhibited, but the onset of action is slow
Solution Approach 1:
The patent describes compounds that directly inhibit factor XIa, preventing the initiation of the amplification loop before thrombin burst occurs, thereby achieving faster onset of anticoagulant effect compared to warfarin which requires time to deplete vitamin K-dependent factors
Solution Approach 2:
The novel macrocyclic compounds possess enhanced pharmacokinetic properties including improved oral bioavailability and faster onset of action compared to warfarin, achieved through optimized molecular structure and mechanism of action that directly blocks factor XIa without requiring factor depletion
3Reliability
If warfarin is used as an anticoagulant, then thrombin generation is inhibited, but dietary and drug interactions are numerous
Solution Approach 1:
The patent targets a specific enzyme (factor XIa) in the coagulation cascade rather than interfering with vitamin K metabolism as warfarin does, thereby eliminating dietary interactions with vitamin K and reducing drug-drug interactions through highly selective enzymatic inhibition
Solution Approach 2:
The patent employs selective factor XIa inhibition as an intermediary mechanism that decouples anticoagulant efficacy from dietary vitamin K intake and concurrent medication use, providing more predictable pharmacokinetics and fewer interactions compared to warfarin's broad mechanism of action
Data Source
AI summary
The present invention provides compounds of Formula (Ia):or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.